744 related articles for article (PubMed ID: 30538286)
21. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
23. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
24. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
25. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
26. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.
Pappas K; Xu J; Zairis S; Resnick-Silverman L; Abate F; Steinbach N; Ozturk S; Saal LH; Su T; Cheung P; Schmidt H; Aaronson S; Hibshoosh H; Manfredi J; Rabadan R; Parsons R
Mol Cancer Res; 2017 Aug; 15(8):1051-1062. PubMed ID: 28483946
[No Abstract] [Full Text] [Related]
27. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
28. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
29. Tumor suppressor p53 and its mutants in cancer metabolism.
Liu J; Zhang C; Hu W; Feng Z
Cancer Lett; 2015 Jan; 356(2 Pt A):197-203. PubMed ID: 24374014
[TBL] [Abstract][Full Text] [Related]
30. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
Wawrzynow B; Zylicz A; Zylicz M
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
Cui Y; Guo G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
[TBL] [Abstract][Full Text] [Related]
33. p53 as a hub in cellular redox regulation and therapeutic target in cancer.
Eriksson SE; Ceder S; Bykov VJN; Wiman KG
J Mol Cell Biol; 2019 Apr; 11(4):330-341. PubMed ID: 30892598
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in p53 research: an interdisciplinary perspective.
Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
[TBL] [Abstract][Full Text] [Related]
35. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernández Borrero LJ; El-Deiry WS
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
[TBL] [Abstract][Full Text] [Related]
36. Promyelocytic leukemia protein is required for gain of function by mutant p53.
Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
[TBL] [Abstract][Full Text] [Related]
37. Mutant p53: it's not all one and the same.
Kennedy MC; Lowe SW
Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
[TBL] [Abstract][Full Text] [Related]
38. Awakening the "guardian of genome": reactivation of mutant p53.
Binayke A; Mishra S; Suman P; Das S; Chander H
Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
[TBL] [Abstract][Full Text] [Related]
39. Improving cancer therapy through p53 management.
Haupt S; Haupt Y
Cell Cycle; 2004 Jul; 3(7):912-6. PubMed ID: 15254405
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome.
Capaci V; Bascetta L; Fantuz M; Beznoussenko GV; Sommaggio R; Cancila V; Bisso A; Campaner E; Mironov AA; Wiśniewski JR; Ulloa Severino L; Scaini D; Bossi F; Lees J; Alon N; Brunga L; Malkin D; Piazza S; Collavin L; Rosato A; Bicciato S; Tripodo C; Mantovani F; Del Sal G
Nat Commun; 2020 Aug; 11(1):3945. PubMed ID: 32770028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]